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Abstract
Liver failure is an increasing problem. Donor-organ shortage results in patients dying before receiving a transplant. Since the
liver can regenerate, alternative therapies providing temporary liver-support are sought. A bioartificial-liver would
temporarily substitute function in liver failure buying time for liver regeneration/organ-procurement. Our aim: to develop a
prototype bioartificial-liver-machine (BAL) comprising a human liver-derived cell-line, cultured to phenotypic competence
and deliverable in a clinical setting to sites distant from its preparation. The objective of this study was to determine
whether its use would improve functional parameters of liver failure in pigs with acute liver failure, to provide proof-of-
principle. HepG2cells encapsulated in alginate-beads, proliferated in a fluidised-bed-bioreactor providing a biomass of 4–
661010cells, were transported from preparation-laboratory to point-of-use operating theatre (6000miles) under
perfluorodecalin at ambient temperature. Irreversible ischaemic liver failure was induced in anaesthetised pigs, after
portal-systemic-shunt, by hepatic-artery-ligation. Biochemical parameters, intracranial pressure, and functional-clotting were
measured in animals connected in an extracorporeal bioartificial-liver circuit. Efficacy was demonstrated comparing
outcomes between animals connected to a circuit containing alginate-encapsulated cells (Cell-bead BAL), and those
connected to circuit containing alginate capsules without cells (Empty-bead BAL). Cells of the biomass met regulatory
standards for sterility and provenance. All animals developed progressive liver-failure after ischaemia induction. Efficacy of
BAL was demonstrated since animals connected to a functional biomass (+ cells) had significantly smaller rises in intracranial
pressure, lower ammonia levels, more bilirubin conjugation, improved acidosis and clotting restoration compared to
animals connected to the circuit without cells. In the +cell group, human proteins accumulated in pigs’ plasma. Delivery of
biomass using a short-term cold-chain enabled transport and use without loss of function over 3days. Thus, a fluidised-bed
bioreactor containing alginate-encapsulated HepG2cell-spheroids improved important parameters of acute liver failure in
pigs. The system can readily be up-scaled and transported to point-of-use justifying development at clinical scale.
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Introduction
Both acute and acute-on-chronic liver failure are well recog-
nised. Liver failure resulting from viral hepatitis, obesity, alcohol
abuse, and drug-induced injury presents major clinical problems.
Whilst organ transplantation is potentially curative, there is a huge
gap between organ availability and supply. Since the liver has the
ability to repair and regenerate given time, alternative therapies
are sought.
Liver support devices, bioartificial livers, aim to provide
temporary synthetic and detoxificatory function buying time
either for liver repair and regeneration, or acting as a bridge to
transplantation [1]. Purely artificial liver support devices, for
example, those based on albumin dialysis did not significantly
improve survival in recent clinical trials [2,3], likely reflecting the
complex functional repertoire of the liver that only a device
containing a biological component can provide.
To achieve adequate function in a bioartificial liver (BAL), the
choice of liver cells, the format of biomass provision, and
bioreactor design are paramount.
Several bioartificial liver machines have been trialled utilising
primary porcine or human hepatocytes at a scale equivalent to 5–
10% in vivo human liver mass [4]. We and others have argued
that a successful bioartificial liver to treat patients should be of
human origin, for reasons including safety, zoonosis risk and
potential species incompatibility in protein/protein receptor
interaction. Thus whilst pig cells are readily available they have
disadvantages in all these respects including protein-protein
compatibility [5]. Primary human hepatocytes are not readily
available, as good-quality explant livers are used for transplanta-
tion. An alternative is the use of human-derived liver cell lines,
such as the ELAD system using the C3A subclone of HepG2 cells
and other experimental devices with Hepa RG cells [6] and a fetal
liver cell line [7].
We have developed a BAL biomass comprising HepG2 cells in
alginate beads of ,500–600 um diameter. In this system, single
HepG2 cells in the cell-beads rapidly multiply to form multicel-
lular spheroids of aggregated cells, with close cell-to-cell contact
mimicking that in vivo. In this system we showed that, in contrast
to conventional monolayer culture in which various functions are
only expressed at low levels, alginate encapsulation imposing
three-dimensional growth increases a broad range functions up to
ten-fold, often approximating in vivo levels [8]. The cytochrome
P450 3A function in our 3-dimensional culture format is within the
range of freshly isolated primary human hepatocytes in culture,
although the urea cycle is incomplete [9,10]. Moreover, in this
culture format, HepG2 cells create a rich extracellular matrix, and
this combines with the three dimensional format to maximise
function [11].
A key concern in BAL design is the presence or absence of a
barrier to diffusion between cells and patient plasma, as BAL
designs should maximise transfer of toxic metabolites from the
blood to the cells for detoxification, and molecules synthesised by
the biomass (eg clotting factors, carrier proteins) must readily
reach the patient circulation.
To house alginate-encapsulated HepG2 cells, we and others
developed a fluidised bed-based bioreactor (FBB) [12–15]. In this,
cells are kept in continued motion under the force of upward flow
of media and downward force of gravity, and this differs from
packed bed reactors in which cells are immobile. Thus the
fluidised bed bioreactor increases mass transfer. Moreover, the
FBB imposes no physical filtration barrier between the biomass
and the circulation, the plasma directly accessing the alginate
hydrogel beads, and can be readily up-scaled for clinical usage by
simply increasing the volume of alginate beads and geometry of
the biomass chamber
For this study, we charged the device with alginate beads
containing 4–661010 HepG2 cells, equivalent to 20–40% of
human hepatocyte biomass (based on the assumption of 1–261011
hepatocytes in 1.2–1.5 kg human liver) to treat pigs. This desired
biomass was estimated from data suggesting survival is possible
with 10–30% residual liver mass, but taking into account that the
milieu of acute liver failure plasma may be detrimental to biomass
viability [16].
The objective of this study was to assess its value in a large
animal model. We used pigs with acute ischaemic liver failure
surgically induced (20–30 kg bw; liver weights of 900–1300 g).
Importantly, the experiment compared animals treated with the
cell-containing BAL to animals undergoing an identical surgical
and anaesthetic protocol with the use of an acellular BAL i.e. an
identical bioreactor containing alginate beads from which HepG2
cells were absent.
The alginate beads were generated at a central expert tissue
culture facility and transported to a distant hepatology centre for
assessment in ALF, and to enable this, a short-term cold-chain
system was developed.
Using this model, we demonstrated improvements in several key
clinical parameters of acute liver failure, including intracranial
pressure (ICP), blood clotting function, bilirubin conjugation,
acidosis and protein synthesis, not found when animals were
treated with the BAL without cells.
Methods
Ethics Statement
Animal experiments were performed under approval from
University of Cape Town (UCT), Faculty of Health Sciences
Animal-Ethics Committee, according to the UCT Animal Unit
health/welfare guidelines. Application No.:009/019, 26/03/09.
Production of alginate-encapsulated hepatocytes and
culture to liver cell spheroids for BAL investigation
The method for production of the cellular component of the
BAL has been described elsewhere [12]. In brief, it can be divided
into two steps (a&b).
(a) HepG2 Monolayer Cell Culture for ELS production
HepG2 verification. Cells were assessed independently for
cell line identity using two methods, microsatellite genotyping and
DNA bar coding (HPA, Porton Down UK); for mycoplasma using
qPCR and two cell culture-based assays, Hoechst dye with
indicator Vero cells, and agar plate growth of conditioned media
from cultured cells, according to Eu Pharm Current Edition
Section 2.6.7 Mycoplasmas (Vitrology, Scotland UK); and in
house for several human pathogens. Sterility was assessed via
direct inoculation methods according to Eu Pharm Current
Edition; Section 2.6.1Sterility and USP Current Edition
,71.Sterility tests (Vitrology, Scotland, UK).
Monolayer culture conditions. HepG2 cells were obtained
from the ECACC (Wiltshire, UK) and maintained in modified
MEM-alpha medium (Gibco, Paisley, UK) supplemented with
10% FBS (Hyclone, Loughborough, UK), 100 IU/ml penicillin
and 0.1 mg/ml streptomycin. Medium was changed every 2–3
days. Cells were counted under light microscopy using a
haemocytometer; viability was assessed using trypan blue dye
exclusion.
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(b) Alginate Encapsulation and Culture of ELS
Alginate encapsulation of HepG2 cells was performed as
described previously. In brief, 80% confluent monolayer cultures
were trypsinised and encapsulated in 1.0% alginate (alginic acid
sodium salt Macrocystis pyrifera kelp) [17]. Alginate beads, contain-
ing cells were resuspended in culture medium at a ratio of 1:58.
Culture expansion in a fluidised bed bioreactor was carried out for
11 days [12]. Medium was changed every 2–3 days unless
otherwise stated. Bead diameters and cell numbers were assessed
on day 0 and at time of harvest.
Short term cold chain
Alginate beads containing HepG2 cell-spheroids were trans-
ported from the laboratory where they were cultured to the point
of use between distinct layers of oxygenated perfluorodecalin
(PFC) and culture medium in a ratio of 1:1:10 at ambient
temperature, with 50% air volume. Antioxidants (500 IU/ml
catalase (Sigma-C9322), 0.85 mM Trolox (Sigma-238813) and
3 mM N-acetyl cysteine (Sigma-A8199), valine (Sigma-V0500),
25mMHEPES buffer (Gibco-15630) were added to reduce
oxidative stress, and maintain pH ,7.4. Prior to use, beads were
washed with normal saline containing 1.7 mM CaCl2 and re-
suspended in heparinised pig plasma. Viability was determined
before and after PFC storage using dual staining with fluorescein
diacetate (FDA, live cells) and propidium iodide (PI, dead cells),
quantified using image-analysis.
BAL circuit set-up
The BAL chamber contained 1100 ml alginate bead suspension
comprising 4.2961.661010 (6SD, n= 6) HepG2 cells as optimally
functional spheroids. Heparinised normal pig plasma was used to
prime both primary and secondary circuits. The biomass was
fluidised at 400–600 ml/min to achieve a 2-fold bed-height.
Temperature was maintained at 37uC; oxygenation was provided
in the chamber via porous tubing at 1000 cc/min.
Surgical Procedures
Large 25–30 kg White-x-Landrace female pigs [n= 13] were
acclimatized in the Animal Unit 7 days prior to surgery. Prior to
inducing ischaemic acute liver failure, pigs were fasted overnight.
They then received continuous anaesthesia throughout with
induction using doses of zoletil, butorphanol and medetomidine
for tracheal intubation, followed by maintenance with isoflurane,
oxygen and nitrous oxide via an endotracheal tube. Fluid
management comprised 0.9%saline at 20 ml/kg/hr and boluses
of 0.9%saline to maintain stroke volume variation ,15% and a
CVP of 10 mmHg. Glucose was monitored hourly, and 5% or
10% glucose in normal saline was given if glucose levels fell below
4 mmol/L to maintain normoglycaemia at a glucose level of
$4 mmol/L. No extra blood products were given during the
process. Intracranial pressure and brain oxygenation monitoring
catheters were inserted via a burr hole, and in some animals intra-
cerebral microdialysis catheters. A 2-hour period was allowed to
reach a steady-state baseline. Continuous vasopressor support was
not given, however at the time of connection of pig to BAL a small
bolus dose of Ornipressin (,2units) was titrated to counteract the
transient drop in blood pressure observed on connection. Animals
remained under continuous anaesthesia until the end of the
procedure and were humanely euthanased with 3 g potassium
chloride as required by the Animal Ethics Committee.
Ischaemic acute liver failure
In the supine position, pressure monitoring vascular catheters
were inserted into the femoral artery and the internal jugular vein.
The abdomen was opened via a midline incision and ligamentous
attachments of the liver divided. The hepatic artery and bile duct
were ligated and divided, portal vein and infrahepatic vena cava
dissected. A side-to-side portacaval shunt was created and liver
rendered totally ischaemic by ligating the portal vein above the
shunt [18,19]. Catheters were inserted into the splenic (venous
outflow) and external jugular vein (venous return) for attachment
to the extracorporeal circuit of the BAL via a COBE-Spectra
plasmapheresis machine (Figure 1). The pigs were connected to
the COBE-Spectra with 90 ml/min blood flow (40–47 ml/min
plasma) in a primary circuit, ,2.5 hours after establishment of
ischaemia. Separated plasma entered the secondary circuit at 400–
600 ml/min and was then recirculated several times through the
BAL chamber; there was continuous return of plasma to the
patient via the COBE-Spectra blood circuit at 90 ml blood/min
(Figure 1). The BAL remained connected to the pig for up to
8 hours, prior to rinseback/disconnection, and animals were killed
and tissues harvested for histology. Two groups of pigs were
compared, each with ischaemic acute liver failure: Group 1 (Gp 1)
were treated with a BAL containing cell-bead biomass, Group 2
(Gp 2, non-functional BAL) treated identically, but with empty-
alginate-bead completely devoid of cell bio-mass. Death was
defined by a mean arterial pressure of,40 mmHg for 30 minutes,
if this occurred before the end of the 8 h bioartificial liver
procedure.
Monitoring
Haemodyamic monitoring consisted of routine ECG, pulse
oximetry and end tidal carbon dioxide. Continuous cardiac output
(PCCI) was monitored using the PiCCO-plus (Pulse Contour
Continuous Cardiac Output, Pulsion Medical Systems SE,
Germany) via CVP measurement in right internal jugular vein
and femoral artery cannulae. Biochemical parameters were
measured by an accredited Chemical Pathology laboratory
(Pathcare, South Africa) as would occur in a clinical patient
setting. Blood samples were taken into heparinase cups for
thromboelastography (TEG) coagulation parameter assessment
(TEG, Haemonetics, MA, USA). Codman Express Intracranial
pressure (ICP-Codman-Raynham-MA, USA) probes and Lycox
brain oxygenation probes (Integra, NJ, USA) monitored brain
function. Blood Glucose was estimated hourly, and blood gases at
multiple time points during the procedure.
Human proteins were measured in pig plasma using ELISA for
human albumin, alpha-1-antitrypsin, alpha-1-acid glycoprotein,
fibrinogen and prothrombin. These antibodies showed no cross
reactivity with porcine proteins. Amino acids were analysed by
high-performance-ion-exchange chromatography [20].
Results
Cell line characterisation
The HepG2 cell bank used, was proven to be identical with the
original deposited cell source, was entirely of human origin, was
not contaminated by any mycoplasma species and met sterility
criteria required for human use in a cell therapeutic. Moreover,
after a screen, more extensive than used for clinical liver
transplantation, the following viruses were undetected: Parvovirus,
HHV6, HSV/VZV, HSV 1&2, EBV, adenovirus, the full
respiratory panel (Flu A&B, RSV, Rhino, Paraflu 1–3, hMPV),
Hepatitis B, Hepatitis C, and Polyoma viruses JC and BK.
Bioartificial Liver for Treatment of Liver Failure
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Viability of biomass
The viability of encapsulated cell mass was 90.7062.3% at the
end of the 11 day conditioning culture. We have previously shown
that exposure to mild cold-chain storage as described in Methods
did not alter the viability of the BAL biomass for up to 48 h [12].
Therefore, in the current trial on ALF, an upper limit of 48 h cold
chain was set. After transport conditions, the BAL viabilities were
88.5668.53%, which was not significantly different from the
starting viability (93.2568.26%, n= 6,mean 6SD, NS). More-
over, proliferation continued so that the overall viable cell number
remained the same (at harvest, 4.2961.661010; after 2 days on
PFC 4.5461.4961010 cells.
Surgical model for ALF
Liver and body weights were the same for both studied groups:
Group 1 (Gp1 cell bead BAL) 26.862.3 kg bw, n= 6, mean6SD;
liver weight 11736122 g vs. Group 2 control (Gp2 empty bead
non-functional BAL) 26.763.4 kg bw, n= 7, mean6SD; liver
weight 11136209 g). Fig 1A shows the time course for the
establishment of the ischaemic ALF model; Fig 1B illustrates the
BAL circuit, and its integration into conventional plasmapheresis
technology.
Chemical pathology in response to ischaemic ALF
Table 1 illustrates the liver function in both ALF groups after
ischaemia prior to BAL treatment. The data represent the range of
measurements routinely performed in chemical pathology to assess
patients presenting clinically with ALF. At the start of BAL
therapy, the groups were comparable in the measured indices
(Table 1). With the establishment of total liver ischaemia via the
portocaval shunt and ligation of the hepatic artery: ammonia
increased at the time the portocaval shunt was created;
international normalised ratio (INR), lactate and bilirubin
increased after ,2 hours of ischaemic ALF. After addition of
BAL in Group 1 (active BAL +cell biomass), conjugated bilirubin
increased with a concomitant decrease in unconjugated bilrubin;
in contrast, in Group 2 (non-functional - empty beads without cells
BAL), unconjugated bilirubin increased progressively, with little
increase in conjugated bilrubin (Figure 2A). Parameters of acid-
base balance acidosis (pH, acid-base-excess, lactate, bicarbonate)
Figure 1. Protocol of ischaemic acute liver failure model. (A) Pigs were treated with the bioartificial liver machine 2–3 h after establishing
ischaemic damage. After anaesthesia, brain monitoring catheters were inserted, prior to establishment of porta-caval shunt and arterial, venous and
urine catheter placement. (B) Schematic of the bioartificial liver machine: The fluidised-bed bioreactor chamber containing either cell bead
biomass (Group 1) or empty beads for control (Group2), was attached to the pig via a plasmapheresis machine. Blood was obtained from the pig via
the splenic vein at 90 ml/min and separated from cellular components with a Cobe Spectra Plasma separator, providing plasma at a flow rate of
,45 ml/min in a primary circuit, feeding into the BAL secondary circuit at ,400–600 ml/min. Whole blood was returned to the pig via the plasma-
separator at 90 ml/min, combining the ‘‘treated ’’plasma with the cellular component.
doi:10.1371/journal.pone.0082312.g001
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showed the expected changes associated with ischaemic hepatic
damage in both groups; improvements in these indices of
circulatory physiology were seen in Group 1, whereas these
parameters did not improve in Group2 (non-functional BAL).
Improved pH control from nadir values early in ALF to end of
BAL treatment reached statistical significance for Group 1
(p = 0.03, n = 4, unpaired, equal variances, 1-tailed) but as
expected, this was not achieved in Group 2 (p= 0.4), see
Figure 2B. Ammonia levels were lower in Group 1 but not in
Group 2 (Fig 2C).
Cerebral physiology in response to ALF
In both groups, intracranial pressure (ICP) increased after
induction of ischaemic liver damage. BAL addition initiated a brief
immediate decrease in ICP in both groups, suspected to be
associated with dilution of the pig circulating plasma volume with
normal plasma from the primed system in the COBE. Thereafter,
ICP continued to rise in the control BAL group (Group 2), but not
in the cell-bead BAL treated group (Group 1) (Fig 3A). The brain
oxygenation response was more variable. After ischaemia was
induced, there was a progressive decrease in brain oxygenation in
some animals, whilst others exhibited a period of presumed
hyperemia before decline. (Fig 3B). After BAL addition, there was
an improvement in oxygenation in Group 1 vs. Group 2. Analysis
of brain metabolites was achieved for four pigs. Fig.4 shows a
typical trace for glucose, and lactate:pyruvate ratios in each side of
the brain demonstrating a decrease in glucose and increase in
lactate:pyruvate ratios in the control empty BAL treated pig
compared with glucose maintenance and no increase in lactate:-
pyruvate ratio in cell bead treated pig.
Plasma amino acids
Derangement in plasma amino acid balances are a feature of
ALF. 10 amino acids increased from start to end of treatment in
Group 1 and 13 amino acids increased in Group 2; 4 amino acids
decreased in Group 2, whilst in Group 1, 7 amino acids decreased
(Table-2). The change from start to end of treatment was
significant in each group.
Synthetic function
Human proteins were detected in plasma from all Group 1 pigs,
and none in Group 2 (Figure 5). Albumin, alpha-1-acid
glycoprotein fibrinogen and alphafoetoprotein (AFP) were detect-
able at all time points after BAL addition. Plasma human Alpha-1-
antitrypsin and prothrombin levels, were assessed only at 4 h after
BAL, and in Group 1 were 0.55760.05 mg/ml and
0.29160.04 mg/ml respectively; Group 2 control pigs exhibited
no human proteins.
Clotting
Thromboelastography (TEG) measurements were used to assess
clotting dysfunction and possible correction by the active BAL
biomass. Not all pigs developed severe coagulopathy, however, in
those that did cell-bead Group 1 animals demonstrated a
restoration of clotting as estimated by TEG K and R times, angle
and MA values, whilst Group 2 showed no improvement
(Figure 6). In both groups initially coagulation parameters
worsened during liver failure. BAL treatment from 2.5 h effected
a general improvement in Group 1, in contrast to Group 2 where
parameters continued to decline. For example, the time taken for
fibrin formation is increased during liver failure; as the BAL
caused an improvement in Group 1, the time taken for fibrin to
form was reduced; in contrast in Group 2 the time continued to
increase. The K time, indicating intrinsic clotting factor activity, as
well as fibrinogen and platelet function decreased in Group 1 with
continued treatment whereas those in Group 2 continued to
increase. The alpha angle in Group 1 pigs increased with BAL
treatment, in Group 2 animals the angle decreased with time. The
Figure 2. Efficacy of HepG2-Fluidised-bed bioreactor treatment
in pigs with ischaemic acute liver failure: biochemical re-
sponse. A) Bilirubin conjugation in pigs with ischaemic acute
liver failure. Conjugated bilirubin concentrations (mmol/L) increased
and unconjugated bilirubin concentrations decreased in Group 1 pigs,
when attached to the cell-bead BAL; in contrast there was neither
increase in conjugated bilirubin nor decrease in unconjugated bilirubin
in Group 2 control animals, Group 1 n=6; group-2 n= 5; p-value,
unpaired 2-tailed t-test, mean6SEM. B). Change in acidosis in pigs
with ischaemic acute liver failure, after BAL treatment. pH
values dropped after ischaemic insult to a nadir in both groups. Blood
pH was assessed in a blood gas analyser. Pigs in the Cell-bead BAL
(Group 1 solid line) showed an increased pH towards normal at the end
of BAL treatment whereas pigs treated with the control empty bead
BAL (Group 2 -----) showed little improvement; inset shows group
averages (n = 4, mean6SEM unpaired, one-tailed t-test). C) Blood
ammonia levels in pigs 4 h after BAL treatment. values show a
change in ammonia from 0.5 h after ischaemia (normalised to 100%)
during BAL treatment. Concomitant with a decrease in ICP in Group 1,
ammonia levels decreased (cell BAL) cf. group 2 (Control empty bead
BAL); Group 1 n= 6, mean 12068; Group 2 n=7, mean 150611.
Statistics: two-tailed unpaired t-test, p = 0.035.
doi:10.1371/journal.pone.0082312.g002
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maximum amplitude on the trace (MA), indicated the absolute
strength of the clot was stronger in Group 1 compared with Group
2 animals (see also Fig 6A&B).
Survival
As intended, all animals died whilst under anaesthesia and
observation, without recovery being attempted. Average survival
time after establishment of ischaemic ALF in Group 1 (active BAL
+cells biomass) was 10.46+/20.7 h, that of Group 2 (control non-
functional BAL) was 8.63+/21.4 hours. This was a non-signifi-
cant trend towards longer stabilisation in Group 1. Extraneous
supportive interventions from the anaesthetists (as might normally
be administered alongside clinical bioartificial liver suport therapy)
were precluded by the study design.
Haemodynamic variables
As expected central blood pressure dropped significantly on
creation of the porto-systemic shunt as part of the ALF model, and
on initial connection to the COBE, but this rapidly corrected.
Cardiac output increased predictably as liver failure progressed,
largely due to a progressive drop in systemic vascular resistance
(SVRI), which was similar in both groups. Haemodynamic data,
which was not significantly different between the two groups, is
summarised in Fig S1. Extra-vascular lung water (EVLW) also
increased indicating acute lung injury in the Group 2, but less so in
Group 1 (Fig-S2A-) during the first 4 hours of BAL treatment,
albeit not statistically significantly different. Cerebral perfusion
pressure (CPP) did not differ between the two groups (Fig S2B).
Histological analysis after death demonstrated patchy ischaemic
necrosis throughout the liver, without engorgement of gut, similar
in both groups. Patchy brain ischaemia was also demonstrable.
Histology of the other organs was normal. (Fig S3).
Discussion
Liver transplantation is the established treatment for acute liver
failure, and is effective by providing complete functional liver
support almost immediately. However, future trends, spurred on
by the lack of donor organs, justify the exploration of alternatives,
such as cell based therapies. We have investigated the role of a
liver cell line cultured in a 3-dimensional format housed in a
fluidised bed bioreactor to provide temporaray liver support in a
near clinical model.
Important goals in liver support therapy include provision of
synthetic and detoxification functions, restoration of blood
coagulability, protection from intracranial hypertension as well
as a positive impact on the inflammatory response of acute liver
failure, with an indication that regeneration of the injured liver is
occurring [1]. To assess all these in a single animal model is
challenging, since ideally both a predicatable rate of onset of liver
damage, and the potential for survival should occur.
The model of surgical ischaemic acute liver failure in pigs
mimics well the clinical scenario where there is a universal increase
in plasma ammonia, acidosis and raised intracranial pressure in
contrast to some unpredictability in drug-induced acute liver
failure models in out-bred pigs [21]. With the surgical model all
animals will suffer ischaemic acute liver damage, although clearly
the predictable deterioration and irreversible liver damage does
not provide an appropriate model to investigate any impact on
survival. The clinical outcome of this ischaemic model is a
consequence both of deficient hepatic function due to the necrotic
liver combined with deleterious effects of substances released from
the necrotic liver into the circulation. The release of substances
from the liver is evidenced by the rising plasma transaminase levels
demonstrating leakage from the liver into the plasma. The
deleterious consequences of the presence of a necrotic liver on
patients’ systemic physiology has been clearly indicated by
demonstration of clinical improvement when the necrotic liver is
removed in Acute Liver failure prior to salvage liver grafting.
(Prolonged anhepatic state after early liver graft removal.[22] We
have demonstrated improvement in important aspects of acute
liver failure in pigs treated with our active BAL biomass. Acidosis,
conjugation of bilirubin, and ammonia improved. The decreased
ammonia levels were indeed unexpected since HepG2 cells are
known to lack a full urea cycle, (being deficient in Ornithine
transcarbamylase at the mRNA level) as do C3A cells [9,10]. One
explanation for the decreased ammonia may be the consumption
of some amino acids at a significant rate by the biomass, removing
the substrate for ammonia generation. The amino acid profiles did
differ between the two groups after treatment. Notably also,
HepG2 cells have a second amino acid transport systems (System
ASC – sodium dependent amino acid transporter) not found in
primary hepatocytes that results in rapid glutamine uptake, which
may also enhance ammonia elimination [23,24].
Synthetic function was clearly demonstrated by the active BAL
biomass, with human proteins assayed appearing at progressively
rising levels in the pigs’ plasma in Group 1. The lack of any
Figure 3. Brain parameters in pigs with ischaemic acute liver
failure. A) Intracranial Pressure (ICP) using a Codman catheter was
recorded every 15 min, in mmHg. The rise after established acute
ischaemic liver failure was halted when pigs were attached to the cell
bead BAL (Group 1, n = 5, closed circles?), whilst it continued to increasein Group 2 (empty bead BAL open circles o), n = 7. B) Brain oxygenation,
normalised to 100% at time of ischaemia. There was an increase in brain
oxygenation in Group 1 cell bead treated pigs (solid circles?) comparedwith Group 2 (open circles o). Statistics compared the slopes of the line
between groups with 95% confidence limits.
doi:10.1371/journal.pone.0082312.g003
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Figure 4. Parameters of brain homeostasis during BAL treatment of pigs with ischaemic liver failure: Brain metabolites.
Microdialysate samples (18 ml) were collected from catheters on each side of the brain. Fig 4 A&B show glucose levels in the brain during the course
of treatment using a cell-bead BAL (4A) or an empty bead BAL control (4B). Left and right refer to left and right brain hemispheres. 30 minute
microdialysates were collected; measurements made hourly. Fig 4C&D show the lactate:pyruvate ratio indicating ischaemic damage in cell-bead BAL
(4C) and empty bead BAL control (4D); note that 4D shows different results on each side of the brain, perhaps indicating patchy brain ischaemia.
These results are representative of the 4 pigs in which microdialysis was performed, two in Group 1 and two in Group 2.
doi:10.1371/journal.pone.0082312.g004
Table 2. Amino acid concentrations in pig plasma before and after treatment.
amino acid
cell-bead
BAL start
cell-bead BAL
end
control empty
bead BAL start
control empty bead
BAL end amino acid cell BAL control BAL
Asp 18.561 18.362 15.762 24.064 Asp decrease increase
Thr 214632 287.6630 148635 267657** Thr increase increase
Ser+Asn+Gln 541650 974652** 509635 9896139* Ser+Asn+Gln increase increase
Glu 203654 178631 227633 232656 Glu decrease increase
Gly 11886109 1583677* 1221665 17296182* Gly increase increase
Ala 7966104 11396164* 8566111 11566157** Ala increase increase
(Cys)2 30.366 27.467 24.762 34.966 (Cys)2 decrease increase
Val 362635 223615* 312641 253622 Val decrease decrease
Met 56.665 111613* 47.964 102618* Met increase increase
Ile 168621 80610* 140621 100613* Ile decrease decrease
Leu 268626 155617* 237633 187620* Leu decrease decrease
Tyr 104612 16967** 77.5611 154622** Tyr increase increase
Phe 106.366 195621* 87.3612 198631** Phe increase increase
His 109.567 131610 98.4610 137616** His increase increase
Lys 437628 557667 300635 523689* Lys increase increase
Arg 115628 0** 139611 8.866** Arg decrease decrease
Pro+Cys 312633 499636** 280624 483660** Pro+Cys increase increase
Amino acids, measured in pig plasma by ion exchange HPLC were quantified in Group 1 and Group 2 animals. Results expressed as mmol/L, mean6SEM. Differences
between start and end of treatment for each group (Group 1 cell-bead BAL n= 6, and Group 2 empty bead non-functional control BAL n = 5), are show with statistical
differences: *p,0.05; **p,0.02, t-test, paired, 2-tailed. Three amino acids showed differences in response to treatment with the BAL comparing Group 1 and Group 2.
doi:10.1371/journal.pone.0082312.t002
Bioartificial Liver for Treatment of Liver Failure
PLOS ONE | www.plosone.org 8 December 2013 | Volume 8 | Issue 12 | e82312
increases in Group 2 confirms the specificity of the assays. It is
noteworthy, that in future clinical application production of AFP
by the biomass may provide a helpful specific tracer as this is rarely
present in plasma of patients with acute liver failure. Fibrinogen
and prothrombin are likely contributing to the improvement of
clotting function, which we measured by Thromboelastography
(TEG), assessed to be a better measure of clotting dysfunction than
prothrombin time and aPTT in a model of hypothermia and
haemorrhagic shock in swine [25]. TEG measures several
parameters of clotting function, reflecting viscoelastic properties
of blood, platelet activation, fibrin formation and retraction of the
clot [26,27]. The R-time reflects fibrin formation rate, functionally
dependent on clotting factors, and particularly fibrinogen; for their
derivation see Fig 4. The K time, reflects viscoelasticity, intrinsic
clotting factor activity, as well as fibrinogen and platelet function.
The alpha angle and MA reflect the absolute strength of the clot.
In the animals in whom clotting was grossly deranged, those in the
Group 2-control showed no correction, whilst in Group 1 this
returned to near normal values. This improvement was noted after
several hours of BAL treatment consistent with the appearance of
human fibrinogen in pig plasma [25].
The provision of freshly synthesised albumin by the biomass
may be of particular significance. Much of previous artificial, non-
biological, liver machine work is based on a form of albumin
dialysis. Whilst none so far has improved survival, there is
symptomatic relief, for example, of pruritis in some patients, and
that is associated with the removal of certain toxins by the
albumin. However, one issue that has emerged is the source and
thus biological efficacy of the albumin in such systems and its
fitness-for-purpose to act as a carrier protein to aid detoxification.
Commercially isolated/prepared albumin has an altered affinity
for toxins which makes it considerably less effective. In contrast the
HepG2 cells are continuously making endogenous nascent
albumin at the time of need, and in our system the per cell
production is indeed equivalent to that calculated from human in
vivo albumin production data [8]; this nascent albumin has been
unaffected by the preservatives e.g. caprylate, used in preparing
commercial albumin and which has been shown to adversely affect
toxin binding [28].
A striking clinical observation was that the intracranial pressure
increase, resulting from ischaemic acute liver damage, was
arrested in pigs treated with the cell-bead BAL. Cerebral perfusion
Figure 5. Human proteins in pig plasma after BAL treatment. Pig blood samples were assessed by ELISA for specific human protein content
during treatment; Group 1 cell bead treated BAL (solid symbols), compared with Group 2 empty bead control treated BAL (open circles) (A) Albumin
(B) Fibrinogen, (C) Alpha-1-acid glycoprotein (A1AGP) and (D) Alphafoetoprotein (AFP). Results expressed as mg/ml pig plasma: mean6SEM n= 6. No
human protein was detected in Group 2 animals, establishing the specificity of the assays for human proteins.
doi:10.1371/journal.pone.0082312.g005
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pressures were identical in both groups. This resolution of ICP in
Group 1 could have had a trivial explanation had it been
associated with a parallel change in cerebral perfusion pressure,
since diminished brain perfusion would also ultimately decrease
ICP. However, this was not the case; both groups had identical
profiles for cerebral perfusion pressure, indicating a specific
decrease in intracranial pressure. Interestingly, in the clinical
situation an ICP value of $30 mmHg in man is associated with
brain herniation and a poor prognostic outcome; the values in the
control group rose above 35 mmHg whereas those in the cell
treated group plateaued lower than 30 mmHg.
Clearly the improvements in biochemical and systemic mani-
festations of acute liver failure reported here are only partial.
Obviously, in a pig model, human derived cells do not substitute
ideal function. However, despite possible incompatibilities, we
demonstrated important improvements in parameters relevant to
acute liver failure using Hep G2 cells.
Whilst human primary hepatocytes might be considered the
ideal cells for use in man, and have been used [29], accessing such
cells on a rapid, sufficient and regular basis is unlikely. Primary
hepatocytes rapidly lose differentiated function in culture and
scarcely proliferate. Proliferating hepatocytes derived from stem
cells are a potentially attractive source, but are not yet a reality.
Current possibilities therefore, for a human source, are cell-lines,
derived either spontaneously, e.g. HepG2 (or C3A), Hepa RG, or
by immortalization, generally viral transformation. Whilst HepG2
cell lines do not express the full in vivo repertoire of function when
cultured as conventional monolayers [9], their function is
Figure 6. Thromboelastography (TEG) measurements of coagulation.                                          A&B) Example of TEG traces: in cell-bead treated BAL Group 1
(A) Thromboelastography of blood
during treatment with either Cell bead treated BAL (solid symbols) or empty bead control treated BAL (open symbols); n = 3: results for each pig are
shown as a change from the start of ischaemia (normalized and denoted as 0 on Y axis), demonstrate changes in R-time (C), K-time (D), angle (E) and
maximum amplitude (MA) (F). BAL was added ,2.5h later. The four parameters describe the overall clotting reaction. The R-time (min) reflecting
fibrin formation rate, is functionally dependent on clotting factors, notably fibrinogen; reported as the reaction time from placement in the cup to
2mm amplitude on the tracing, thus, the higher the number the longer it takes for formation of clot. In both groups initially the time taken for fibrin
formation is increased during liver failure; as the BAL effects an improvement in Group 1, the time taken for fibrin to form is reduced; in contrast in
Group 2 the time continues to increase (C). The K time, reflecting viscoelasticity, is the time taken from the R time to the point where the trace
amplitude reaches 20mm, indicating intrinsic clotting factor activity, as well as fibrinogen and platelet function. Similar to the R time, the longer the
time the less intrinsic clotting factor activity; pigs in Group 1 show a decrease in K time with continued treatment whereas those in Group 2 continue
to increase (D). The alpha angle (angle of slope of r to k denotes rate of clot formation); in Group 1, pigs had an increased angle with BAL treatment,
in Group 2 animals the angle decreased with time (E). MA is the maximum amplitude on the trace, reflecting the absolute strength of the clot; Group
1 pigs showed a stronger clot compared with Group 2 animals (F).
doi:10.1371/journal.pone.0082312.g006
Bioartificial Liver for Treatment of Liver Failure
PLOS ONE | www.plosone.org 10 December 2013 | Volume 8 | Issue 12 | e82312
q(B). Clotting parameters q  uantified (C-F):     and empty bead control treated BAL Group 2
markedly up-regulated when the same cells are cultured in a three-
dimensional format mimicking in-vivo architecture [8,30]. Many
3-D culture approaches necessitate use of products of animal
origin e.g. collagen, matrigel etc.; one advantage of our 3-D
culture system is use of the non-animal product alginate, derived
from seaweed, providing the substrate for cell attachment required
by epithelial cells. Notably this system differs from the use of
polycation-coated alginate, in which after encapsulation and
polycation-coating, the hydrogel is dissolved; furthermore that
process introduces a diffusion barrier, e.g. Poly-L-lysine molecular
weight cut-off is 70,000Da. [31–33].
It is also worth noting that several other cell bioreactors
introduce a molecular barrier. In the ELAD and other systems
using hollow-fibre technology to house the biomass, cells are
separated from patient blood or plasma by a semi-permeable
membrane [34–37], which, however, limits exchange and mass
transfer. One notable exception is the AMC BAL, in which plasma
contacts cells directly [38,39].
Previously, we demonstrated that [17,40] HepG2 cells in alginate
perform synthetic and detoxification functions in the presence of
both normal and acute liver failure plasma, and in a small animal
model of acute liver failure induced with acetaminophen [41],
improved haemodynamics using a small-scale packed-bed bioreac-
tor. Here, using the superior technology of a fluidised-bed
bioreactor on a near human scale (,561010 cells in 1100 ml), we
have demonstrated improvements in a pig acute liver failure model
and thus provided proof-of-principle for alginate-encapsulated
HepG2 cells in a fluidised-bed bioreactor. It may be noted that
this BAL design could be adapted for any proliferating human liver
cell-line available in the future. Our calculations - based as indicated
on the requirement to provide 30-50% of liver mass - suggest that
scaling up for human could provide the required 761010 to
,161011 cells in 1600–2000 ml, a volume compatible with clinical
use in a bioreactor.
In order to test the potential for clinical translation, experiments
were organised with production of the BAL spheroids at a central
facility and subsequently transportation to a distant hepatology
centre, reflecting the way in which it would required to be used in
practice. This is the way that clinical hepatology services are
organised in many parts of the world. A robust and exacting
system was established which required transport of more than
6000 miles by air and road to where the ALF model was set up by
developing a short term cold chain enabling transport over 48 h at
ambient temperature prior to use. Whilst this will not provide
long-term storage at cryo-temperatures, it would be sufficient for
delivery to any hospital that requires it; the perfluorodecalin
required is available in GMP clinical grade, and is sterilisable by
autoclaving [42]. For the future, we have demonstrated previously
that the functional unit of this biomass, the alginate bead
containing HepG2 cell-spheroids, can be cryopreserved with
recovery of function within 48 hours, a timeframe suitable for
subsequent clinical use [43,44]. To our knowledge no other
bioreactor design enables the biomass to be cryopreserved at
optimal function prior to use, enabling an ‘‘off the shelf’’ product
to treat patients. Moreover, we have recently utilised a non-liquid
nitrogen cryocooler to effect the cryopreservation with encourag-
ing results [45], further confirming this bioreactor design to be
compatible with clinical use in a worldwide setting.
Further work to enable a disposable cryopreservable chamber
for clinical scale biomass cryopreservation is ongoing. We are now
in the process of refining design and manufacture of this system to
GMP to provide a clinically ready bioartificial liver machine.
Supporting Information
Figure S1 Haemodynamic data in pigs with ischaemic
acute liver failure treat with control or cell-bead BAL.
Haemodynamic data was obtained using a PiccoPlus monitor and
picco software for data collection. Solid lines are animals in Group
1 (cell-bead treated); dashed lines are animal treated with empty
bead non-functional control BAL. A&B show Mean Arterial
Pressure in mmHg; C&D show cardiac output represented by
PCCI in L/Min/m3; E&F show Systemic Vascular Resistance
(SVRI) in dyns/second/cm2. Each is shown in time (hours) after
ischaemia insult during BAL treatment.
(TIF)
Figure S2 Further haemodynamic variables. 2A) Extra-
vascular lung water was measured using the Picco plus machine at
intervals after BAL addition. The average values were lower in the
cell-bead treated group compared with control group indicating
less fluid overload in the treated group. Extravascular lung water,
a measure of oedema, is important during treatment of liver
failure. 2B) cerebral perfusion pressure did not differ between
control and treated groups.
(TIF)
Figure S3 Histology of liver after ischaemic damage. A)
liver x4-scale-bar-500 mm, B) Liver x40, C&D) brain x40; H&E.
scale-bar 50 um.
(TIF)
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